The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and …

K Dheda, T Gumbo, G Maartens, KE Dooley… - The Lancet …, 2019 - thelancet.com
Summary The Lancet Respiratory Medicine Commission on drug-resistant tuberculosis was
published in 2017, which comprehensively reviewed and provided recommendations on …

Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline

P Nahid, SR Mase, GB Migliori, G Sotgiu… - American journal of …, 2019 - atsjournals.org
Background: The American Thoracic Society, US Centers for Disease Control and
Prevention, European Respiratory Society, and Infectious Diseases Society of America …

Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in …

N Ndjeka, JR Campbell, G Meintjes… - The Lancet Infectious …, 2022 - thelancet.com
Background There is a need for short and safe all-oral treatment of rifampicin-resistant
tuberculosis. We compared outcomes up to 24 months after treatment initiation for patients …

Multidrug and extensively drug-resistant tuberculosis: epidemiology, clinical features, management and treatment

S Tiberi, A Zumla, GB Migliori - Infectious Disease Clinics, 2019 - id.theclinics.com
MDR-TB is a lethal form of TB caused by Mycobacterium tuberculosis strains, which are
resistant to rifampicin and isoniazid. It should be suspected in patients living in high MDRTB …

[HTML][HTML] Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort

S Koirala, S Borisov, E Danila, A Mariandyshev… - Pulmonology, 2021 - Elsevier
Abstract The World Health Organization (WHO) recommends countries introduce new anti-
TB drugs in the treatment of multidrug-resistant tuberculosis. The aim of the study is to …

Functional impact of sequelae in drug-susceptible and multidrug-resistant tuberculosis

M Muñoz-Torrico, S Cid-Juárez… - … of Tuberculosis and …, 2020 - ingentaconnect.com
BACKGROUND: Evidence on the impact of tuberculosis (TB) treatment on lung function is
scarce. The aim of this study was to evaluate post-treatment sequelae in drug-susceptible …

Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety

JT Gao, J Du, GH Wu, Y Pei, MQ Gao… - Infectious Diseases of …, 2021 - Springer
Abstract Background World Health Organization recommends countries introducing new
drug and short treatment regimen for drug resistant tuberculosis (DR-TB) should develop …

Designing molecular diagnostics for current tuberculosis drug regimens

SB Georghiou, M de Vos, K Velen, P Miotto… - Emerging microbes & …, 2023 - Taylor & Francis
Diagnostic development must occur in parallel with drug development to ensure the
longevity of new treatment compounds. Despite an increasing number of novel and …

Advances in the application of 1, 2, 4-triazole-containing hybrids as anti-tuberculosis agents

Y Cao, H Lu - Future Medicinal Chemistry, 2021 - Taylor & Francis
Tuberculosis is a deadly communicable disease caused by the bacillus Mycobacterium
tuberculosis (MTB), and pulmonary tuberculosis accounts for over 80% of the total cases …

[HTML][HTML] Risk factors for early mortality in patients with pulmonary tuberculosis admitted to the emergency room

R Singla, B Raghu, A Gupta, JA Caminero, P Sethi… - Pulmonology, 2021 - Elsevier
Background and objectives Mortality of patients with pulmonary tuberculosis (TB) admitted to
emergency departments is high. This study was aimed at analysing the risk factors …